You just read:

Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA® through 48 Weeks

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Apr 11, 2019, 07:59 ET